<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618782</url>
  </required_header>
  <id_info>
    <org_study_id>LEVI-04-21-02</org_study_id>
    <nct_id>NCT05618782</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Levicept</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Bioscience Clinical Development (NBCD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Levicept</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, randomized, double-blind, placebo-controlled trial of multiple doses and&#xD;
      multiple administrations of LEVI-04 for the treatment of pain due to osteoarthritis of the&#xD;
      knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a Screening Period (including a Diary Run- In/analgesic wash-out&#xD;
      Period), Randomization, Post-Randomization Period, and a Follow-up Period. Up to 624&#xD;
      participants will be enrolled and randomized to one of four Treatment Arms at the ratio&#xD;
      1:1:1:1&#xD;
&#xD;
      The overall objective of this study is to evaluate the efficacy and safety of LEVI-04&#xD;
      compared to placebo in patients with knee OA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2022</start_date>
  <completion_date type="Anticipated">December 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled trial of multiple doses and multiple administrations of LEVI-04 for the treatment of pain due to osteoarthritis of the knee. The study consists of a Screening Period (including a Diary Run- In/analgesic wash-out Period), Randomization, Post-Randomization Period, and a Follow-up Period. Up to 624 participants will be enrolled and randomized to one of four Treatment Arms at the ratio 1:1:1:1.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double- Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of LEVI-04 (multiple doses) compared to placebo in reducing pain due to knee OA.</measure>
    <time_frame>up to 17 weeks</time_frame>
    <description>Change in WOMAC pain subscale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of LEVI-04 (multiple doses) compared to placebo in improving physical function.</measure>
    <time_frame>up to 17 weeks</time_frame>
    <description>Change in StEPP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of LEVI-04 (multiple doses) compared to placebo in improving physical function.</measure>
    <time_frame>up to 17 weeks</time_frame>
    <description>Change in WOMAC Physical function subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of LEVI-04 (multiple doses) compared to placebo in improving joint stiffness.</measure>
    <time_frame>up to 17 weeks</time_frame>
    <description>Change in WOMAC Stiffness subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of LEVI-04 (multiple doses) compared to placebo in Patient Global Assessment (PGA).</measure>
    <time_frame>up to 17 weeks</time_frame>
    <description>Change in PGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate rescue medication use in the LEVI-04 group (multiple doses) compared to placebo.</measure>
    <time_frame>up to 20 weeks</time_frame>
    <description>Rescue Medication usage during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of responders based on various levels of reduced pain in participants receiving LEVI-04 (multiple doses) compared to placebo.</measure>
    <time_frame>up to 17 weeks</time_frame>
    <description>Change in average weekly NRS score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">624</enrollment>
  <condition>Pain</condition>
  <condition>Osteo Arthritis Knee</condition>
  <condition>Knee Osteoarthritis</condition>
  <condition>Arthritis</condition>
  <condition>Joint Diseases</condition>
  <condition>Musculoskeletal Diseases</condition>
  <condition>Rheumatic Diseases</condition>
  <arm_group>
    <arm_group_label>0.3 mg/kg dose intravenous infusion of LEVI-04</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg/kg dose intravenous infusion of LEVI-04</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.0 mg/kg dose intravenous infusion of LEVI-04</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LEVI- 04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc).It modulates the nerve growth factor (NGF) pathway, clinically proven to provide effective analgesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose intravenous infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEVI-04</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>0.3 mg/kg dose intravenous infusion of LEVI-04</arm_group_label>
    <arm_group_label>1.0 mg/kg dose intravenous infusion of LEVI-04</arm_group_label>
    <arm_group_label>2.0 mg/kg dose intravenous infusion of LEVI-04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo:</intervention_name>
    <description>Placebo dose intravenous infusion</description>
    <arm_group_label>Placebo dose intravenous infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent form (ICF).&#xD;
&#xD;
          2. Male or female participants between ≥40 and ≤80 years of age.&#xD;
&#xD;
          3. BMI ≤40 kg/m2.&#xD;
&#xD;
          4. The ability to utilize the eDiary device provided by study sites.&#xD;
&#xD;
          5. History of knee pain on most days for at least 3 months prior to Screening&#xD;
&#xD;
          6. Confirmation of OA of the knee&#xD;
&#xD;
               1. Radiographs of both knees with a Posterior-Anterior, Fixed-flexion view taken&#xD;
                  during the Screening Period.&#xD;
&#xD;
               2. American College of Rheumatology (ACR) clinical and radiographic diagnostic&#xD;
                  criteria.&#xD;
&#xD;
          7. Evidence of knee OA with a KL grade ≥2, determined through central reading.&#xD;
&#xD;
          8. Target Knee must have a score of ≥20 out of 50 on the WOMAC pain subscale during&#xD;
             Screening and at Randomization&#xD;
&#xD;
          9. The Baseline (NRS) Pain score will be derived from the last seven days of the Diary&#xD;
             Run-In Period and must meet following criteria:&#xD;
&#xD;
               1. Completion of Average Daily (NRS) Pain score on at least 6 of the 7 days.&#xD;
&#xD;
               2. Mean Average Daily (NRS) Pain score must be ≥4.0 and ≤9.0&#xD;
&#xD;
               3. Mean Average Daily (NRS) Pain variability must be ≤1.5&#xD;
&#xD;
         10. If female, not of childbearing potential defined as post-menopausal for at least 1&#xD;
             year, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy), or practicing an agreed upon highly effective method of birth control&#xD;
             throughout the study period.&#xD;
&#xD;
         11. If male and sexually active with partner of childbearing potential, willing to agree&#xD;
             to practice a highly effective method of contraception from Visit 2 and at least 3&#xD;
             months after Visit 11 (week 20).&#xD;
&#xD;
         12. Willing to withdraw from any medication for Osteoarthritis including, but not limited&#xD;
             to, Opioids, Non-Steroidal Anti-inflammatories (NSAIDs), COX-2 inhibitors, Topical&#xD;
             medication, and Duloxetine.&#xD;
&#xD;
         13. Participant agrees to take only the allowed Rescue Medications from the start of the&#xD;
             Diary Run-In Period through study completion (maximum 4000 mg paracetamol per day).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of OA of other major joints (including but not limited to nontarget knee)&#xD;
             that could interfere with assessment of pain due to OA of the target knee, in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
          2. Current comorbid condition, other than OA, known to be significantly associated with&#xD;
             arthritis or joint pathology, including but not necessarily limited to autoimmune&#xD;
             disease with significant joint involvement (e.g., Rheumatoid Arthritis or Paget's&#xD;
             disease; Seronegative Spondyloarthropathies (e.g. Ankylosing Spondylitis, Psoriasis&#xD;
             arthritis, Reactive arthritis); or other systemic disease involving the target knee&#xD;
             (including endocrinopathies).&#xD;
&#xD;
          3. The following conditions should be excluded: Known presence of rapidly Progressive&#xD;
             Osteoarthritis (RPOA), primary osteonecrosis (including spontaneous osteonecrosis of&#xD;
             the knee), subchondral insufficiency fractures (SIF), avascular necrosis, osteoporotic&#xD;
             fractures, atrophic OA, excessive malalignment of the knee (anatomical axis angle&#xD;
             greater than 10 degrees), pathological fractures, or stress fracture or reaction,&#xD;
             vertical tear of the posterior meniscal root, or large or extensive subchondral cysts,&#xD;
             or target knee anserine or patellar bursitis of clinical relevance&#xD;
&#xD;
          4. Hip dislocation and congenital hip dysplasia with degenerative joint disease should be&#xD;
             excluded.&#xD;
&#xD;
          5. History of gout with recent (&lt; 6 months) pain flares and uncontrolled uric acid&#xD;
             levels. Participants with a history or diagnosis of pseudogout (calcium pyrophosphate&#xD;
             dihydrate crystal deposition disease) can enroll if there has not been a flare within&#xD;
             6 months prior to screening and use of NSAIDs is not required for management of this&#xD;
             condition.&#xD;
&#xD;
          6. Presence of neuropathic pain deemed likely to interfere with trial endpoints, complex&#xD;
             regional pain syndrome, or chronic widespread pain syndromes e.g., fibromyalgia.&#xD;
&#xD;
          7. History of significant trauma (e.g., intra-articular fracture) or surgery (excluding&#xD;
             injection therapies and arthroscopy) to a knee, hip, or shoulder within the previous 1&#xD;
             year&#xD;
&#xD;
          8. Planned major surgery or other major invasive procedures while participating in the&#xD;
             study.&#xD;
&#xD;
          9. Surgery or stent placement for coronary artery disease in the six months prior to&#xD;
             screening .&#xD;
&#xD;
         10. Nondiagnostic arthroscopy performed on the target knee joint within 180 days prior to&#xD;
             Screening; or diagnostic arthroscopy performed on the target knee joint within 90 days&#xD;
             prior to Screening.&#xD;
&#xD;
         11. Intraarticular injection therapies to the target knee joint within 12 weeks prior to&#xD;
             Screening, or to any non-target joint within 6 weeks prior to Screening.&#xD;
&#xD;
         12. Participants likely to be deemed unfit for joint replacement surgery due to&#xD;
             concomitant illness, in the investigator opinion.&#xD;
&#xD;
         13. Opioid use, including Tramadol, of 4 or more instances per week over the month prior&#xD;
             to Screening.&#xD;
&#xD;
         14. Known history of hypersensitivity to monoclonal antibodies.&#xD;
&#xD;
         15. Presence of any medical condition or unstable health status that, in the judgment of&#xD;
             the investigator, might adversely impact the safety of the participant.&#xD;
&#xD;
         16. Signs and symptoms of significant cardiac disease, including but not limited to&#xD;
             established ischemic heart disease, peripheral arterial disease and /or&#xD;
             cerebrovascular disease (unstable angina, myocardial infarction, cardiovascular&#xD;
             thrombotic events, transient ischemic attacks, and stroke in the six months prior to&#xD;
             screening)&#xD;
&#xD;
         17. Active malignancy or history of malignancy within the past 5 years, with exception of&#xD;
             resected and cured basal cell carcinoma and squamous cell carcinoma of the skin.&#xD;
&#xD;
         18. Clinically significant abnormal laboratory parameter(s) and/or ECG parameter(s) during&#xD;
             Screening, that, in the judgment of the Investigator, would preclude the participant&#xD;
             from participation in this study.&#xD;
&#xD;
         19. Participation in other studies involving investigational drug(s) within 30 days (or 90&#xD;
             days for biologics) prior to screening.&#xD;
&#xD;
         20. History of Carpal Tunnel Syndrome with symptoms within one year of Screening or a&#xD;
             Boston Carpal Tunnel Questionnaire (Symptom Severity Scale) mean score ≥3.&#xD;
&#xD;
         21. A total Symptom Impact score on the Survey of Autonomic Symptoms ≥3.&#xD;
&#xD;
         22. Pregnant or breast feeding.&#xD;
&#xD;
         23. Previously received any form of anti-NGF&#xD;
&#xD;
         24. Requires walker or wheelchair for mobility (walking stick permitted).&#xD;
&#xD;
         25. Active or historic substance abuse within one year of Screening in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
         26. Medical history within 5 years of Screening that involves suicidal ideation, suicide&#xD;
             attempt, or increased risk of suicide as assessed by the Investigator.&#xD;
&#xD;
         27. Presence of any contraindication to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Westbrook</last_name>
    <role>Study Director</role>
    <affiliation>Levicept</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iwona Bombelka</last_name>
    <phone>01304 799760</phone>
    <email>info@levicept.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire Herholdt</last_name>
    <phone>01304 799760</phone>
    <email>info@levicept.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CCR Brno, s.r.o</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petra Kopeckova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCR Czech a.s</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lukas Rocnak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCR Prague, s.r.o</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maryna Pesek</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanos Clinic Nordjylland</name>
      <address>
        <city>Gandrup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Flye Jensen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanos Clinic Herlev</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Kolstrup</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanos Clinic Syddanmark</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anette Rasmussen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hong Kong Center for Clinical Research</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ella Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMSI Cardiology Institute/RTL SM SRL Consultative ward</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tatiana Rotaru</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMSI Clinical Republican Hospital &quot;Timofei Mosneaga&quot;</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dorian Sasu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NZOZ Bif-Med. s.c.</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamila Stankiewicz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Hetmańska</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Konrad Obst</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Somed CR</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrianna Chrominka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Somed CR</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jakub Kierzkowski</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Hong Kong</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <keyword>Levi-04</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

